Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
|
|
Ra Pharmaceuticals, Inc. (RARX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/13/2020 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 04/09/2020 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/06/2020 |
SC 13D/A
| NEW ENTERPRISE ASSOCIATES 13 LP has filed a Schedule 13D for Ra Pharmaceuticals, Inc. |
| 04/03/2020 |
10-K/A
| Annual Report for the period ended December 31, 2019 [amend] |
| 04/03/2020 |
4
| NEW ENTERPRISE ASSOCIATES 13 LP (10% Owner) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 6,135,234 shares
@ $0 |
|
| 04/03/2020 |
4
| Mathers Edward T (Director) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 15,000 options to buy
@ $22.37, valued at
$335.6k
Disposed/sold 15,000 options to buy
@ $9.9, valued at
$148.5k
Disposed/sold 15,000 options to buy
@ $19.88, valued at
$298.2k
|
|
| 04/03/2020 |
4
| Treco Douglas A (President and CEO) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 234,707 shares
@ $48, valued at
$11.3M
Disposed/sold 139,371 options to buy
@ $2.87, valued at
$400k
Disposed/sold 241,460 options to buy
@ $2.87, valued at
$693k
Disposed/sold 164,285 options to buy
@ $5.6, valued at
$920k
Disposed/sold 225,000 options to buy
@ $16.64, valued at
$3.7M
Disposed/sold 125,000 options to buy
@ $7.33, valued at
$916.3k
Disposed/sold 311,000 options to buy
@ $21, valued at
$6.5M
Disposed/sold 20,833 restricted stock units
@ $0 |
|
| 04/03/2020 |
4
| Lubner David Charles (Executive VP and CFO) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 15,622 shares
@ $48, valued at
$749.9k
Disposed/sold 115,572 options to buy
@ $2.87, valued at
$331.7k
Disposed/sold 92,283 options to buy
@ $2.87, valued at
$264.9k
Disposed/sold 28,571 options to buy
@ $5.6, valued at
$160k
Disposed/sold 112,500 options to buy
@ $16.64, valued at
$1.9M
Disposed/sold 62,500 options to buy
@ $7.33, valued at
$458.1k
Disposed/sold 133,000 options to buy
@ $21, valued at
$2.8M
Disposed/sold 10,416 restricted stock units
@ $0 |
|
| 04/03/2020 |
4
| Ricardo Alonso (See Remarks) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 2,973 shares
@ $48, valued at
$142.7k
Disposed/sold 2,857 options to buy
@ $0.84, valued at
$2.4k
Disposed/sold 14,285 options to buy
@ $2.87, valued at
$41k
Disposed/sold 30,000 options to buy
@ $2.87, valued at
$86.1k
Disposed/sold 31,428 options to buy
@ $5.6, valued at
$176k
Disposed/sold 60,000 options to buy
@ $16.64, valued at
$998.4k
Disposed/sold 26,250 options to buy
@ $7.33, valued at
$192.4k
Disposed/sold 107,000 options to buy
@ $21, valued at
$2.2M
Disposed/sold 4,375 restricted stock units
@ $0 |
|
| 04/03/2020 |
4
| Read Simon (Chief Scientific Officer) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 12,595 shares
@ $48, valued at
$604.6k
Disposed/sold 46,434 options to buy
@ $2.87, valued at
$133.3k
Disposed/sold 26,422 options to buy
@ $2.87, valued at
$75.8k
Disposed/sold 25,000 options to buy
@ $5.6, valued at
$140k
Disposed/sold 67,500 options to buy
@ $16.64, valued at
$1.1M
Disposed/sold 55,000 options to buy
@ $7.33, valued at
$403.2k
Disposed/sold 107,000 options to buy
@ $21, valued at
$2.2M
Disposed/sold 9,166 restricted stock units
@ $0 |
|
| 04/03/2020 |
4
| Farzaneh-Far Ramin (Chief Medical Officer) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 14,492 shares
@ $48, valued at
$695.6k
Disposed/sold 11,110 options to buy
@ $5.6, valued at
$62.2k
Disposed/sold 73,654 options to buy
@ $5.6, valued at
$412.5k
Disposed/sold 90,000 options to buy
@ $16.64, valued at
$1.5M
Disposed/sold 62,500 options to buy
@ $7.33, valued at
$458.1k
Disposed/sold 133,000 options to buy
@ $21, valued at
$2.8M
Disposed/sold 10,416 restricted stock units
@ $0 |
|
| 04/03/2020 |
4
| Cumbo Alexander (Director) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 15,000 options to buy
@ $19.88, valued at
$298.2k
Disposed/sold 25,000 options to buy
@ $12.99, valued at
$324.8k
|
|
| 04/03/2020 |
4
| PEARSON TIMOTHY R (Director) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 22,857 options to buy
@ $2.87, valued at
$65.6k
Disposed/sold 15,000 options to buy
@ $22.37, valued at
$335.6k
Disposed/sold 15,000 options to buy
@ $9.9, valued at
$148.5k
Disposed/sold 15,000 options to buy
@ $19.88, valued at
$298.2k
|
|
| 04/03/2020 |
4
| King John C (Chief Commercial Officer) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 10,823 shares
@ $48, valued at
$519.5k
Disposed/sold 190,000 options to buy
@ $6.2, valued at
$1.2M
Disposed/sold 107,000 options to buy
@ $21, valued at
$2.2M
Disposed/sold 30,658 restricted stock units
@ $0 |
|
| 04/03/2020 |
4
| Shah Rajeev M. (10% Owner) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 4,858,260 shares
@ $48, valued at
$233.2M
Disposed/sold 15,000 options to buy
@ $22.37, valued at
$335.6k
Disposed/sold 15,000 options to buy
@ $9.9, valued at
$148.5k
Disposed/sold 15,000 options to buy
@ $19.88, valued at
$298.2k
|
|
| 04/03/2020 |
4
| Heft Robert (Director) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 22,857 options to buy
@ $2.87, valued at
$65.6k
Disposed/sold 15,000 options to buy
@ $22.37, valued at
$335.6k
Disposed/sold 15,000 options to buy
@ $9.9, valued at
$148.5k
Disposed/sold 15,000 options to buy
@ $19.88, valued at
$298.2k
|
|
| 04/03/2020 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 4,858,260 shares
@ $48, valued at
$233.2M
|
|
| 04/03/2020 |
4
| Brennan Aoife (Director) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Disposed/sold 15,000 options to buy
@ $19.88, valued at
$298.2k
Disposed/sold 25,000 options to buy
@ $16.36, valued at
$409k
|
|
| 04/02/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/02/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/02/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/02/2020 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 04/02/2020 |
POSASR
| Form POSASR - Post-effective Amendment to an automatic shelf registration statement: |
| 04/02/2020 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 04/02/2020 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 04/02/2020 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/31/2020 |
8-K
| Quarterly results |
| 03/18/2020 |
4
| Ricardo Alonso (See Remarks) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Sold 2,288 shares
@ $44.25, valued at
$101.2k
|
|
| 03/18/2020 |
4
| Farzaneh-Far Ramin (Chief Medical Officer) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Sold 10,595 shares
@ $45.1648, valued at
$478.5k
Exercised 1,389 options to buy
@ $5.6, valued at
$7.8k
Exercised 9,206 options to buy
@ $5.6, valued at
$51.6k
|
|
| 03/13/2020 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 02/28/2020 |
8-K
| Quarterly results |
| 02/27/2020 |
10-K
| Annual Report for the period ended December 31, 2019 |
| 02/20/2020 |
4
| Farzaneh-Far Ramin (Chief Medical Officer) has filed a Form 4 on Ra Pharmaceuticals, Inc.|
Txns:
| Sold 10,595 shares
@ $46.6116, valued at
$493.8k
Exercised 1,389 options to buy
@ $5.6, valued at
$7.8k
Exercised 9,206 options to buy
@ $5.6, valued at
$51.6k
|
|
| 02/10/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|
|
|